|
Cytopathology
Section
Cytopathology
Staff
Andrea D. Abati,
M.D.
Chief, Cytopathology Section
Laboratory of Pathology
Building 10, Room 2A19
Phone: 301-496-6355
Fax: 301-402-2585
E-mail: abatia@mail.nih.gov
Biography
Dr. Abati is a graduate
of the S.U.N.Y. Buffalo Medical School. She completed residencies in
Anatomic Pathology and Neuropathology at the New York University Medical
Center and fellowships in Surgical Pathology and Cytopathology at Memorial
Sloan-Kettering Cancer Center. Prior to coming to the NCI, Dr. Abati
was a staff pathologist at New York University Medical Center and the
Baylor University Medical Center where she also completed a residency
in Clinical Pathology. She serves on the editorial boards of Diagnostic
Cytopathology, Cancer Cytopathology and Clinical Cancer Research. She
is the secretary for Papanicolaou Society of Cytopathology and the editor
of the newsletter Focus.
Dr. Abati is well
known through her numerous publications and national and international
lectures on her area of expertise, the application of ancillary techniques
to cytopathology. She is a co-author of Modern Cytopathology, a comprehensive
text of cytopathology to be published by W. B. Saunders in early 2003.
Cytopathology Section
The Cytopathology
Section provides complete diagnostic service in cytopathology for the
Clinical Center of the National Institutes of Health. We utilize ancillary
diagnostic techniques such as immunocytochemistry, flow cytometry and
molecular diagnostics when appropriate, to confirm interpretations made
by routine light microscopy or to enhance cytological diagnostic accuracy.
In medical practice today, cytopathology is no longer simply a screening
modality, but rather provides definitive diagnoses which direct patient
care and treatment.
The Cytopathology
Section has an approximate distribution of specimens as follows: FNA,
30 percent; CNS, 33 percent; effusions, 8 percent; respiratory, 9 percent;
GU, 10 percent; cervical/vaginal, 7 percent; GI, 1 percent; miscellaneous,
2 percent. The section has a high rate of malignancy-25 percent of all
accessioned specimens. Due to the nature of the specimen material, a
large number of our cases require immunoperoxidase studies (20 percent).
The immuno-suppressed nature of the patient population dictates that
a significant proportion of our cases requires special studies for pathologic
organisms (10 percent). The relatively high rate of pathologic findings
combined with the diversity of types of exfoliative and FNA specimens
provide a broad experience in diagnostic cytopathology for residency
and fellowship training.
The Cytopathology
Section is involved in several clinically-related research projects,
many of which utilize fine needle aspiration (FNA) and immunocytochemistry
to provide ancillary diagnostic information regarding expression of
various tumor antigens. A partial listing of such studies includes:
(1) evaluation of CD25 antigen in lymphoma FNA specimens as part of
a clinical trial using the monoclonal antibody Tac
(2) semiquantitative analysis of the melanoma associated antigens gp100,
MART-1, and tyrosinase in FNA samples of metastatic malignant melanoma
as well as HLA-A2 status of tumor cells and T cell infiltration in these
lesions for subsequent immunotherapy treatment
(3) morphologic and immunocytochemical evaluation of apheresis specimens
for circulating tumor cells in patients with stage III and IV breast
cancer
(4) immunocytochemical evaluation of lymphoid populations in bronchoalveolar
lavage specimens from patients subsequent to local exposure to endotoxin
(5) evaluation of FNA and frozen tissue biopsies of ovarian cancer for
expression of MoV-18 for immunotherapy treatment
(6) detection of the BK virus/SV40 T antigen in the urine of HIV positive
patients.
(7) pilot trial of sequential neoadjuvant combination chemotherapy with
TX and AC in breast cancer with evaluation of chemotherapy effects on
gene expression
Research projects
include proteomic evaluation of various malignancies for potential diagnostic
use and evaluation of the MXR protein, a newly identified transporter
in multidrug resistance.
Recent
Publications:
Fetsch
PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin
for the detection of mesothelial cells in effusion cytology. Diagnostic
Cytopathology 2001;25(3):158-161.
Fetsch PA, Steinberg
SM, Riker AI, Marincola FM, Abati A. Melanoma antigen expression in
serial fine-needle aspiration samples in patients with metastatic malignant
melanoma participating in immunotherapy clinical trials: a preliminary
look. Cancer 2001;25;93(6):409-14.
Fetsch PA, Abati
A, Immunocytochemistry in effusion cytology-a contemporary review. Cancer
Cytopathology 2001;93:293-308.
Fetsch PA, Brosky
K, Simsir A, Abati A. Preparation of effusion cytology samples for optimal
immunocytochemistry: a comparison of cytospins vs. thinprep vs. cell
blocks. Diagnostic Cytopathology 2002;26(1):61-6.
Dahmoush L, Hijazi
Y, Barnes E, Stetler-Stevenson MA, Abati A. Adult T-cell leukemia/lymphoma:
a cytopathological, immunocytochemical and flow cytometric study. Cancer
Cytopathology (in press).
Filie A, Wilder
A, Brosky K, Kopp J, Arora K, Abati A. Urinary cytology associated with
human BK virus and indinavir in HIV positive patients: a study of 155
cases. AJCP (in press).
Collaborators:
Franco
Marincola, M.D., Surgery Branch, NCI
Steven Rosenberg, M.D., Surgery Branch, NCI
Susan Bates, M.D., Cancer Therapeutics Branch, NCI
Wyndham Wilson, M.D., Medicine Branch, NCI
Richard Little, M.D., AIDS Malignancy Clinical Research Section, NCI
Steven Holland, M.D., National Institute of Allergy and Infectious
Diseases
Patrick Hwu, M.D., Surgery Branch, NCI
Suzanne Topalian, M.D., Surgery Branch, NCI
JoAnne Zujewski, M.D., Medical Oncology Clinical Research Unit, NCI
Jeffrey Kopp, M.D., National Institute of Diabetes and Digestive and
Kidney Diseases
Robert Kreitman, M.D., Laboratory of Molecular Biology, NCI
Aylin Simsir, M.D., Department of Pathology, New York University Medical
Center
Yasmine Hijazi, M.D., Director Cytopathology, American Medical Laboratories
|